(In the Media) “Clinical Trials Using Cancer Treatment for Terminal Nerve Disease「Doctor Led Clinical Trials」Complex Processes Hinder Establishment” (Sankei Shimbun, November 5, 2014) (in Japanese)
date : 11/5/2014
An interview with HGPI’s Executive Director, Toshio Miyata, was featured in the following article:
“Clinical Trials Using Cancer Treatment for Terminal Nerve Disease「Doctor Led Clinical Trials」Complex Processes Hinder Establishment”
(Sankei Shimbun, November 5, 2014) (in Japanese)
「神経の難病に抗がん剤治験「医師主導治験」手続き煩雑で定着せず」
“Clinical Trials Using Cancer Treatment for Terminal Nerve Disease「Doctor Led Clinical Trials」Complex Processes Hinder Establishment”
(Sankei Shimbun, November 5, 2014) (in Japanese)
「神経の難病に抗がん剤治験「医師主導治験」手続き煩雑で定着せず」
Top Research & Recommendations Posts
- [Research Report] The Public Opinion Survey on Cancer Genomics and Precision Medicine (March 9, 2022)
- [Recommendations] Proposal on a Global Procurement System for Coronavirus Disease 2019 (COVID-19) Vaccines (September 7, 2020)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Announcement] HGPI Planetary Health Policy Team Signs Healthy Climate Prescription (August 31, 2022)
- [Joint Report and Recommendations] “Rebalancing Health System: Innovation and Sustainability” A Joint Global Expert Meeting convened by the CSIS and HGPI
